Most Recent
Nike loses challenge to swoosh-like trade mark of Canberra football club
Nike has lost its challenge to a Canberra AFL club's trade mark, with IP Australia finding that the “arc-like feature” depicting a football in flight was not deceptively similar to the sportswear giant’s iconic swoosh mark.
Claws out as Puma appeals Tiger Woods’ brand trade mark
Puma has appealed its failed opposition to a trade mark for Tiger Woods' golf apparel and equipment brand Sun Day Red, which the German sneaker giant argued was too similar to its iconic leaping cat mark.
Samsung Bioepis shoots down Janssen patent for ulcerative colitis biologic
Samsung Bioepis has successfully opposed Janssen's bid to patent a monoclonal antibody to treat ulcerative colitis, but an IP Australia delegate has given the J&J-owned company a chance to fix its application.
‘Argumentative and amorphous’: Startup attacks Fortescue’s call for seized docs in trade secrets row
Green iron startup Element Zero is challenging a bid by Fortescue for access to nine million seized documents in their trade secrets spat, saying its rival has not met the test for proving inadequate discovery of material.
Target, Kmart accused of selling knock-off Van Cleef jewellery
The owner of luxury brand Van Cleef & Arpels has taken retailers Target and Kmart to court, alleging they infringed its trade marks and violated consumer law by selling jewellery that copy its hallmark clover and flower motifs worn by countless celebrities and royalty.
Regeneron, Bayer take fight over Eylea biosimilar to appeals court
Biotech Regeneron and drug company Bayer have wasted no time in challenging a decision that cleared the way for generic pharmaceutical manufacturer Sandoz to launch a version of top selling Eylea.
Fortescue, Element Zero come to blows over discovery again, raising judge’s ire
A judge has expressed frustration over the fourth discovery fight this year in Fortescue’s trade secrets case against Element Zero, as the green iron startup claims its bigger rival is trying to drag out the litigation.
Regeneron, Bayer lose bid to block Sandoz from launching Eylea biosimilar
Regeneron and Bayer have lost their bid to block generic drug maker Sandoz from launching a biosimilar of their blockbuster eye drug Eylea.
Dyno Nobel appeals loss in explosives patent spat with Orica
Explosives company Dyno Nobel is appealing a court's dismissal of its case seeking to invalidate patents owned by rival Orica for a wireless detonation device.
Dyno Nobel’s fight over Orica’s explosives patents fizzles out
Dyno Nobel has lost its bid to invalidate three of explosive manufacturer Orica’s patents for a wireless detonation device, with a judge finding it was liable for patent infringement.